These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

292 related articles for article (PubMed ID: 18383873)

  • 1. Adoptive immunotherapy for pancreatic cancer using MUC1 peptide-pulsed dendritic cells and activated T lymphocytes.
    Kondo H; Hazama S; Kawaoka T; Yoshino S; Yoshida S; Tokuno K; Takashima M; Ueno T; Hinoda Y; Oka M
    Anticancer Res; 2008; 28(1B):379-87. PubMed ID: 18383873
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Adoptive immunotherapy for pancreatic cancer: cytotoxic T lymphocytes stimulated by the MUC1-expressing human pancreatic cancer cell line YPK-1.
    Kawaoka T; Oka M; Takashima M; Ueno T; Yamamoto K; Yahara N; Yoshino S; Hazama S
    Oncol Rep; 2008 Jul; 20(1):155-63. PubMed ID: 18575732
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Immunotherapy for unresectable pancreatic cancer].
    Yahara N; Oka M
    Gan To Kagaku Ryoho; 2002 Mar; 29(3):390-7. PubMed ID: 11915728
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intratumoral immunization with tumor RNA-pulsed dendritic cells confers antitumor immunity in a C57BL/6 pancreatic murine tumor model.
    Schmidt T; Ziske C; Märten A; Endres S; Tiemann K; Schmitz V; Gorschlüter M; Schneider C; Sauerbruch T; Schmidt-Wolf IG
    Cancer Res; 2003 Dec; 63(24):8962-7. PubMed ID: 14695214
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Specific immune against pancreatic cancer induced by dendritic cells pulsed with mutant K-ras peptide].
    Yang B; He Y; Sun DL; Zou Y; Qin XH; Huang BH
    Zhonghua Yi Xue Za Zhi; 2008 Jul; 88(28):1956-60. PubMed ID: 19062734
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adoptive immunotherapy with MUC1-mRNA transfected dendritic cells and cytotoxic lymphocytes plus gemcitabine for unresectable pancreatic cancer.
    Shindo Y; Hazama S; Maeda Y; Matsui H; Iida M; Suzuki N; Yoshimura K; Ueno T; Yoshino S; Sakai K; Suehiro Y; Yamasaki T; Hinoda Y; Oka M
    J Transl Med; 2014 Jun; 12():175. PubMed ID: 24947606
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combination therapy with tumor cell-pulsed dendritic cells and activated lymphocytes for patients with disseminated carcinomas.
    Katano M; Morisaki T; Koga K; Nakamura M; Onishi H; Matsumoto K; Tasaki A; Nakashima H; Akiyoshi T; Nakamura M
    Anticancer Res; 2005; 25(6A):3771-6. PubMed ID: 16302738
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dendritic cell-based immunotherapy of cancer with carcinoembryonic antigen-derived, HLA-A24-restricted CTL epitope: Clinical outcomes of 18 patients with metastatic gastrointestinal or lung adenocarcinomas.
    Ueda Y; Itoh T; Nukaya I; Kawashima I; Okugawa K; Yano Y; Yamamoto Y; Naitoh K; Shimizu K; Imura K; Fuji N; Fujiwara H; Ochiai T; Itoi H; Sonoyama T; Hagiwara A; Takesako K; Yamagishi H
    Int J Oncol; 2004 Apr; 24(4):909-17. PubMed ID: 15010829
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Adoptive immunotherapy for pancreatic cancer, using MUC1 specific CTL].
    Masaki Y; Oka M
    Gan To Kagaku Ryoho; 1996 Oct; 23(12):1679-80. PubMed ID: 8886044
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Induction of lymphokine-activated cytotoxic T lymphocytes stimulated by dendritic cells and autologous tumor from a patient with gastric cancer and their effects in vitro.
    Yoshikawa T; Yanoma S; Tsuburaya A; Kobayashi O; Sairenji M; Motohashi H; Noguchi Y
    Hepatogastroenterology; 2005; 52(61):289-92. PubMed ID: 15783052
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Breast carcinoma cell lysate-pulsed dendritic cells cross-prime MUC1-specific CD8+ T cells identified by peptide-MHC-class-I tetramers.
    Bohnenkamp HR; Coleman J; Burchell JM; Taylor-Papadimitriou J; Noll T
    Cell Immunol; 2004; 231(1-2):112-25. PubMed ID: 15919376
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Therapeutic effects of treatment of pancreatic carcinoma by interleukin-23 and apoptotic cell antigen-modified dendritic cell vaccine: experiment with mice].
    Tan G; Wang ZY; Yin S
    Zhonghua Yi Xue Za Zhi; 2006 Apr; 86(14):943-6. PubMed ID: 16759530
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Human dendritic cells transfected with amplified MUC1 mRNA stimulate cytotoxic T lymphocyte responses against pancreatic cancer in vitro.
    Chen J; Li HY; Wang D; Zhao JJ; Guo XZ
    J Gastroenterol Hepatol; 2011 Oct; 26(10):1509-18. PubMed ID: 21950745
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Feasibility study of adoptive immunotherapy for metastatic lung tumors using peptide-pulsed dendritic cell-activated killer (PDAK) cells.
    Yamaguchi Y; Ohta K; Kawabuchi Y; Ohshita A; Okita R; Okawaki M; Hironaka K; Matsuura K; Toge T
    Anticancer Res; 2005; 25(3c):2407-15. PubMed ID: 16080467
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A phase I-II study of alpha-galactosylceramide-pulsed IL-2/GM-CSF-cultured peripheral blood mononuclear cells in patients with advanced and recurrent non-small cell lung cancer.
    Motohashi S; Nagato K; Kunii N; Yamamoto H; Yamasaki K; Okita K; Hanaoka H; Shimizu N; Suzuki M; Yoshino I; Taniguchi M; Fujisawa T; Nakayama T
    J Immunol; 2009 Feb; 182(4):2492-501. PubMed ID: 19201905
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Preparation of fully activated dendritic cells capable of priming tumor-specific cytotoxic T lymphocytes in patients with metastatic cancer using penicillin-killed streptococcus pyogenes (OK432) and anti-CD40 antibody.
    Kontani K; Teramoto K; Ozaki Y; Sawai S; Tezuka N; Ishida H; Kajino K; Fujino S; Yamauchi A; Taguchi O; Kannagi R; Yokomise H; Ogasawara K
    Oncol Rep; 2007 Apr; 17(4):895-902. PubMed ID: 17342333
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Modulation of MUC1 mucin as an escape mechanism of breast cancer cells from autologous cytotoxic T-lymphocytes.
    Kontani K; Taguchi O; Narita T; Izawa M; Hiraiwa N; Zenita K; Takeuchi T; Murai H; Miura S; Kannagi R
    Br J Cancer; 2001 May; 84(9):1258-64. PubMed ID: 11336479
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cytotoxic effects of T cells induced by fusion protein 6B11-pulsed dendritic cells on ovarian carcinoma cells.
    Yang W; Feng J; Chang X; Fu T; Ye X; Zhang H; Li X; Wen H; Feng L; Tong C; Cui H
    Gynecol Oncol; 2007 Apr; 105(1):238-43. PubMed ID: 17383546
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mucin-1 is expressed on dendritic cells, both in vitro and in vivo.
    Cloosen S; Thio M; Vanclée A; van Leeuwen EB; Senden-Gijsbers BL; Oving EB; Germeraad WT; Bos GM
    Int Immunol; 2004 Nov; 16(11):1561-71. PubMed ID: 15381671
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dendritic cells pulsed with alpha-galactosylceramide induce anti-tumor immunity against pancreatic cancer in vivo.
    Nagaraj S; Ziske C; Strehl J; Messmer D; Sauerbruch T; Schmidt-Wolf IG
    Int Immunol; 2006 Aug; 18(8):1279-83. PubMed ID: 16772371
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.